Leukemia Research
Volume 26, Issue 8 , Pages 721-724 , August 2002

Pilot study of recombinant human soluble tumor necrosis factor receptor (TNFR:Fc) in patients with low risk myelodysplastic syndrome

  • Craig S. Rosenfeld

      Affiliations

    • Suite D-220, 7777 Forest Lane, Dallas, TX 239, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-972-566-7790; fax: +1-972-566-3034
    • ,
  • Cindi Bedell

      Affiliations

    • MSN, OCN, US Oncology, Dallas, TX, USA

Received 22 October 2001 ,Accepted 29 November 2001.

References 

  1. Rosenfeld CR, List A. A hypothesis for the pathogenesis of myelodysplastic syndromes. implications for new therapies. Leukemia. 2000;14:2–8
  2. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088
  3. Quesnel B, Guillerm G, Vereecque R, Wattel E, Preudhomme C, Bauters F, et al.  Methylation of the p15INK4B gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood. 1998;91:2985–2990
  4. Bouscary D, Chen YL, Guesnu M, Picard F, Viguier F, Lacombe C, et al.  Activity of the caspase-3/CPP32 enzyme is increase in early stage myelodysplastic syndromes with excessive apoptosis, but caspase inhibition does not enhance colony formation in vivo. Exp. Hematol. 2000;28:784–791
  5. Zoumbos N, Symeonidis A, Kourakli A, Katevas P, Matsouka P, Perraki M, Georgoulias V. Increased levels of soluble interleukin-2 receptors and tumor necrosis factor in serum of patients with myelodysplastic syndromes. Blood 1991;77:413–14.
  6. Verhoef GEG, De Schouwer P, Ceuppens JL, Van Damme J, Goossens W, Boogaerts MA. Measurement of serum cytokine levels in patients with myelodysplastic syndromes. Leukemia. 1992;12:1268–1272
  7. Stasi R, Brunetti M, Bussa S, Conforti M, Martin LS, Presa ML, et al.  Serum levels of tumour necrosis factor-α predict response to recombinant human erythropoietin in patients with myelodysplastic syndrome. Clin. Lab. Haematol. 1997;19:197–201
  8. Gersuk GM, Beckham C, Loken MR, Kiener P, Anderson JE, Farrand A, et al.  A role for tumour necrosis factor-α, Fas, and Fas-ligand in marrow failure associated with myelodysplastic syndrome. Br. J. Haematol. 1998;103:176–188
  9. Koike M, Ishiyama T, Tomoyasu S, Tsuruoka N. Spontaneous cytokine overproduction by peripheral blood mononuclear cells from patients with myelodysplastic syndromes and aplastic anemia. Leuk. Res. 1995;19:639–644
  10. Kitagawa M, Saito I, Kuwata T, Yoshida S, Yamaguchi S, Takahaski M, et al.  Overexpression of tumor necrosis factor (TNF)-α and interferon (IFN)-γ by bone marrow cells from patients with myelodysplastic syndromes. Leukemia. 1997;11:2049–2054
  11. Kitagawa M, Kamiyama R, Kasuga T. Increase in number of bone marrow macrophages in patients wtih myelodysplastic syndromes. Eur. J. Haematol. 1993;51:56–58
  12. Raza A, Mundle S, Shetty V, Alvi S, Chopra H, Span L, et al.  Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines. Int. J. Hematol. 1996;63:265–278
  13. Nemunaitis J, Rosenfeld C, Getty L, Boegel F, Meyer W, Jennings LW, et al.  Pentoxifylline and ciprofloxacin in patients with myelodysplastic syndrome. Am. J. Clin. Oncol. 1995;18:189–193
  14. Raza A, Qawi H, Lisak L, Andric T, Dar S, Andrews C, et al.  Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine pentoxifylline, and ciprofloxacin with or without dexamethasone. Blood. 2000;95:1580–1587
  15. Molldrem JJ, Caples M, Mavroudis D, Plante M, Young NS. Antithymocyte globulin for patients with myelodysplastic syndrome. Br. J. Haematol. 1997;99:699–705
  16. Jonášová A, Neuwirtová R, Cermák J, Vozobulová V, Mociková K, Šišková M, et al.  Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic marrow. Br. J. Haematol. 1998;100:304–309
  17. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, et al.  Proposals for the classification of the myelodysplastic syndrome. Br. J. Haematol. 1982;51:189–199
  18. Wee S, Pascual M, Eason JD, Schoenfeld DA, Phelan J, Boskovic S, et al.  Biological effects and fate of a soluble, dimeric, 80-kDa tumor necrosis factor receptor in renal transplant recipients who receive OKT3 therapy. Transplantation. 1997;63:570–577
  19. van der Poll T, Coyle SM, Levi M, Jansen PM, Dentener M, Barbosa K, et al.  Effect of a recombinant dimeric tumor necrosis factor receptor on inflammatory responses to intravenous endotoxin in normal humans. Blood. 1997;89:3727–3734
  20. Raza A, Allampallam K, Shetty V, Mundle S, Borok R, Lisak L, Andrews C, Ekbal M, Mazzmoran L, Zorat F, Henderson B, Dangerfield B, Ansaarie I, Hussaini S, Broady-Robinson L, Venugopal P. Biologic and clinical response to recombinant human soluble tumor necrosis factor receptor (Enbrel) in patients with myelodysplastic syndromes (MDS). Blood 1999;94 (Suppl 1, Part 2):171b [Abstract].
  21. Deeg HJ, Gotlib J, Beckham C, Dugan F, Appelbaum F, Greenberg P. Soluble TNF receptor fusion protein (TNFR:Fc Enbrel) in the treatment of patients with myelodysplastic syndrome (MDS). Blood 2000;96:146a [Abstract].
  22. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al.  Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. New Engl. J. Med. 1997;337:141–147
  23. Raza A, Meyer P, Dutt D, Zorat F, Lisak L, Nascimben F, du Randt M, Kaspar C, Goldberg C, Loew J, Dar S, Gezer S, Venugopal P, Zeldis J. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 2001;98(4):958–65.

PII: S0145-2126(01)00201-6

Leukemia Research
Volume 26, Issue 8 , Pages 721-724 , August 2002

Article Tools